关注
Márta Péntek
Márta Péntek
在 uni-obuda.hu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Inequities in access to biologic and synthetic DMARDs across 46 European countries
P Putrik, S Ramiro, TK Kvien, T Sokka, M Pavlova, T Uhlig, A Boonen, ...
Annals of the rheumatic diseases 73 (1), 198-206, 2014
3822014
Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis
F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky
British journal of dermatology 175 (3), 561-571, 2016
2302016
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
V Brodszky, P Baji, O Balogh, M Péntek
The European Journal of Health Economics 15, 65-71, 2014
1602014
EQ-5D in central and Eastern Europe: 2000–2015
F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ...
Quality of Life Research 25, 2693-2710, 2016
1422016
Biosimilars for the management of rheumatoid arthritis: economic considerations
L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek
Expert review of clinical immunology 11 (sup1), 43-52, 2015
1232015
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
P Putrik, S Ramiro, TK Kvien, T Sokka, T Uhlig, A Boonen, ...
Annals of the rheumatic diseases 73 (11), 2010-2021, 2014
1202014
Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003
M Péntek, C Horváth, I Boncz, Z Falusi, E Tóth, A Sebestyen, I Májer, ...
Osteoporosis international 19, 243-249, 2008
1162008
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ...
The European Journal of Health Economics 15, 111-119, 2014
972014
A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi
Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016
922016
Adherence to biologic DMARD therapies in rheumatoid arthritis
T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi
Expert opinion on biological therapy 10 (9), 1367-1378, 2010
842010
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe
M Cavazza, Y Kodra, P Armeni, M De Santis, J López-Bastida, ...
The European Journal of Health Economics 17, 19-29, 2016
832016
Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary
F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ...
Value in Health 23 (9), 1235-1245, 2020
812020
The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries
L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek
Advances in Therapy 34, 1128-1144, 2017
812017
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe
F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A Śliwczyński, ...
World Journal of Gastroenterology: WJG 21 (6), 1728, 2015
812015
Cost-of-illness of patients with systemic sclerosis in a tertiary care centre
T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgar, L Czirjak, ...
Rheumatology 49 (10), 1920-1928, 2010
772010
Assessment of skin involvement in systemic sclerosis
G Kumánovics, M Péntek, S Bae, D Opris, D Khanna, DE Furst, L Czirják
Rheumatology 56 (suppl_5), v53-v66, 2017
732017
Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment
V Brodszky, P Bálint, P Géher, L Hodinka, G Horváth, É Koó, M Péntek, ...
Rheumatology international 30, 199-205, 2009
702009
Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a …
V Brodszky, M Péntek, PV Bálint, P Géher, O Hajdu, L Hodinka, G Horvath, ...
Scandinavian journal of rheumatology 39 (4), 303-309, 2010
672010
A detailed analysis of ‘not relevant’responses on the DLQI in psoriasis: potential biases in treatment decisions
F Rencz, AK Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, ...
Journal of the European Academy of Dermatology and Venereology 32 (5), 783-790, 2018
652018
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients
AK Poór, F Rencz, V Brodszky, L Gulácsi, Z Beretzky, B Hidvégi, P Holló, ...
Quality of Life Research 26, 3409-3419, 2017
652017
系统目前无法执行此操作,请稍后再试。
文章 1–20